Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 601–700 of 786
Zhang, S., Zhang, X., Lou, J., Jing, H., Yan, Z., Wang, Y., Gui, Y., Xu, L., Lyu, X., Lu, Y., et al. (2026) · JACS Au · doi:10.1021/jacsau.6c00022 · Cited by 1
Won, H.-J., Baek, S. M., Lee, M. H., Park, J. H., Shin, J., Yang, Y., Jang, Y. H., Inn, K., & Kim, N. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501208 · Cited by 3
Zhang, J., Li, Y., Han, H., & Zhang, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797535 · Cited by 4
Lyu, X., Wang, Z., Shen, Y., Wang, X., Wang, Y., Yu, S., Yang, B., Yan, Z., Zhang, S., Lu, Y., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118921 · Cited by 1
A destination-driven framework for nanoparticle-enabled targeted protein degradation
Wang, Y., Xia, X., Xie, S., Tong, F., Liu, W., & Gao, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.009 · Cited by 1
Recent Advances in Targeting RNA Splicing Factors with Small Molecules
Yuan, X., & Yang, C. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00234 · Cited by 1
Wang, X., Jia, Z., Kandegama, W., Hao, G., Zhu, B., Pan, L., & Chen, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.06.019 · Cited by 1
The synthetic landscape of cereblon (CRBN) binders: from thalidomide to emerging chemotypes
Rafael, S., Sánchez, C., Whelan, R., Harris, C., Verdaguer, X., Mayor‐Ruiz, C., & Riéra, A. (2026) · Chemical Society Reviews · doi:10.1039/d6cs00247a · Cited by 2
Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
Spielmann, V., Buchloh, J., Selcen, S., Schneider, C., Jansari, S., Fang, X., Duan, N., Demirdizen, E., Krauß, L., Eggert, J., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0670 · Cited by 2
XiaoTian, Z., Wang, Y., & Feng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1926363 · Cited by 1
Jung, S. H., Wang, X., Liu, B., Roy, R. N., Jaiswal, N., Rai, R. K., Takagi, Y., Gao, C., Zeng, L., Lo, H., et al. (2026) · Advanced Science · doi:10.1002/advs.77575 · Cited by 1
Jingele, X., Sun, Q., Li, X., Li, X., Kon, A., Tao, X., & Yoshimi, A. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag140 · Cited by 1
段旭良, Wang, J., Chen, X., Dong, S., & Xu, X. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71675 · Cited by 1
Winter, G. E. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2378 · Cited by 1
Uehara, T., & Owa, T. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.414 · Cited by 1
Rezazadeh‐Jabalbarezi, F., Ranjbar‐Karimi, R., Atabaki, F., & Mohammadiannejad, K. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133909 · Cited by 1
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
History of IMiDs and Protein Degradation as a Pharmacological Modality
Yamamoto, J., Asatsuma‐Okumura, T., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch8 · Cited by 1
Targeting RNA‐binding proteins for cancer therapy
Lu, C., Xu, G., & Ma, J. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.232 · Cited by 1
Novel Technologies in PROTAC Design
Jain, K., Reddy, S. C., Moode, S., Mehra, P., Tarannum, S., Patel, M., Jain, V. K., & Popli, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_5 · Cited by 1
Toxicological Aspects of PROTACs
Pujari, R., & Soni, U. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_10 · Cited by 1
Li, Y., Sun, Q., Yang, Z., LuoMin, Yang, W., Song, Z., Liu, K., Li, H., Gao, W., Wu, Q., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.040 · Cited by 1
Design and Synthesis of 7-(N-Aryl Pyrrolidinyl) Indoles as Potential DCAF15 Binders
Devarajappa, R., Kiyeleko, S., Hocine, S., Cosson, V., Calandrino, R., Baló, T., Bordelo, J. A., Triboulet, S., Caruana, L., Klipfel, L., et al. (2025) · Reactions · doi:10.3390/reactions6010020 · Cited by 1
Kamiya, T., Ajiro, M., Oshima, M., Koide, S., Nakajima‐Takagi, Y., Aoyama, K., Tsuchiya, A., Kaito, S., Itokawa, N., Ito, R., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0340 · Cited by 1
RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Fergany, A., & Tatarskiy, V. V. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200908122402 · Cited by 1
Meeting Proceedings from ICBS 2018—Toward Translational Impact
Mayerthaler, F., Finley, M., Pfeifer, T. A., & Antolín, A. A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00169 · Cited by 1
CRISPR-Suppressor Scanning Unsticks Molecular Glues
Robinson, S. A., & Banik, S. M. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00216 · Cited by 2
Mutant SF3B1 splices a more leukemogenic EVI1
Obeng, E. A. (2022) · Blood · doi:10.1182/blood.2022017380 · Cited by 1
Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader
Jin, H., Fang, J., Myers, J., Singh, S. V., & Yang, J. J. J. (2025) · Scientific Data · doi:10.1038/s41597-025-06408-4 · Cited by 2
An epigenetic bifunctional that toggles between transactivation and repressionPreprint
Sadagopan, A., Carson, M., Zamurs, E. J., Srikonda, S., Weiss, C. N., Bond, M. J., Sodhi, A., Donovan, K. A., Ryan, J. K., Fischer, E. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712509 · Cited by 1
Uehara, T., & Owa, T. (2017) · KAGAKU TO SEIBUTSU · doi:10.1271/kagakutoseibutsu.55.800
Li, Y. (2018) · Deep Blue (University of Michigan)
Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives
Fink, E. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Patent Highlights June–July 2019
Mucke, H. A. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0019
Modulation of the CRL4CRBN E3 Ubiquitin Ligase by Thalidomide Analogs
Sievers, Q. L. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Development of Small Molecule Kinase Degraders as Chemical Biology Probes and Cancer Therapies
Dobrovolsky, D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
CellMinerCDB for Integrative Genomics and Pharmacogenomics Analyses of Cancer Cell LinesPreprint
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S. R., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3192032
Cancer Targets Involving the Ubiquitin Proteasome System
Araujo, E. M. V. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc282
Microbiome Augmented Therapeutic Interventions for a Healthy Oral System
Hashim, N. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00013-9
Inducing Ubiquitylation and Protein Degradation as a Drug Development Strategy
Dhami, K., & Huang, X. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_9
Idegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Liafjell, T. A. (2014) · NVA (Nasjonalt vitenarkiv)
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Thang, D. C. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/155657
Zheng, N. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736847231.793569035
Chiang, C. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735998607.793561779
Hoppe, T. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731966527.793570381
Chiang, C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737836027.793574330
Djurić, S. W. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738423203.793580622
Dawson, M. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738066001.793575550
Kostić, M., & Jones, L. H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch15
Extending the Degradation Toolkit – mRNA Targeting as an Alternative Means to Affect Protein Levels
Ursu, A., Herdy, B., & Osadnik, H. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch9
Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11
A Structural and Biophysical Perspective of Degrader Activity Through Ternary Complex Formation
Gadd, M. S., & Aublette, M. C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch4 · Cited by 1
Cui, F., Wang, W., Zhuang, C., & Wang, P. (2023) · Research Square · doi:10.21203/rs.3.rs-2750988/v1
Alternative Splicing and Cancer
Choksi, A., Pant, R., Nakka, K. K., Singh, M., Upreti, A., & Chattopadhyay, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_3
Drugs that modulate resistance to antitumor agents
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00007-8
Research progress in small-molecule modulators of protein-protein interactions
Yang, B., & Qi, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0034
Jablonowski, C. M., Quarni, W., Singh, S. V., Tan, H., Bostanthirige, D. H., Jin, H., Fang, J., Chang, T., Finkelstein, D., Cho, J., et al. (2023) · eLife · doi:10.7554/elife.90993.1 · Cited by 1
Thalidomid: Fluch, Segen und Triumph eines Schlafmittels
Giannis, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-67510-6_11
Kozicka, Z. (2023) · Science · doi:10.1126/science.adl4288
Fine-tuning chemical genetics to identify physiologic drug targets
Vostal, L. E., & Kapoor, T. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.10.017
Jablonowski, C., Quarni, W., Singh, S., et al. (2024) · eLife · doi:10.7554/elife.90993.2.sa1
Jablonowski, C. M., Quarni, W., Singh, S. V., Tan, H., Bostanthirige, D. H., Jin, H., Fang, J., Chang, T., Finkelstein, D., Cho, J., et al. (2024) · eLife · doi:10.7554/elife.90993.2.sa3
APSiC: Analysis of Perturbation Screens for the Identification of Novel Cancer Genes
Montazeri, H., Coto‐Llerena, M., Bianco, G., Zangene, E., Taha‐Mehlitz, S., Paradiso, V., Srivatsa, S., de Weck, A., Roma, G., Lanzafame, M., et al. (2020) · Figshare · doi:10.5281/zenodo.3661028
Barraza, S. J., & Woll, M. G. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch7
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450.1 · Cited by 1
Adhikari, B., Schneider, K., Diebold, M., et al. (2024) · eLife · doi:10.7554/elife.98450.1.sa1
Adhikari, B., Schneider, K., Diebold, M., et al. (2024) · eLife · doi:10.7554/elife.98450.1.sa0
Xia, J., Norris, J. K. S., Mackinnon, M., & Butterworth, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100015 · Cited by 1
Targeted protein degradation using thalidomide and its derivatives
Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007
RNA Modifying Proteins: Emerging Targets for Drug Discovery
Boriack‐Sjodin, P. A., & Silver, S. J. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00500
Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part3
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450.2
Arnet, L., Emilius, L., Hamann, A., Carmo‐Fonseca, M., Berking, C., Dörrie, J., & Schaft, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030368
Assessing the Stability of Molecular Glues with Weighted Ensemble Simulations
Atik, S. B., & Dickson, A. (2026) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6c00319
Design and Synthesis of E7820/Tasisulam Hybrids as Potential DCAF15 Binders
Hocine, S., Cosson, V., Calandrino, R., Baló, T., Bordelo, J. A., Triboulet, S., Caruana, L., Klipfel, L., Calis, S., Herner, A., et al. (2025) · Reactions · doi:10.3390/reactions6020034
Farnaby, W. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01897-1
Inducers of Targeted Protein Degradation as Drug Candidates for Neurodegenerative Disorders
Tomoshige, S., & Ishikawa, M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch11 · Cited by 1
Molecular Glues as Activators for PPI
Qi, X. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch13
Progress on molecular glue degraders
Chen, J., Deng, Z., Li, H., & Liu, L. (2026) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0228
Yan, W., Zhang, N., Liu, X., He, Q., Lv, X., Sun, J., Zhuang, L., Zou, Y., Liang, Y., Liang, Y., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112064
Targeting the Ubiquitin-Proteasome System in cancer
Spallek, R., McLaughlin, C., & Sapkota, G. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00078-9
Hülskamp, M. D., Kronenberg, D., & Stange, R. (2021) · Figshare · doi:10.6084/m9.figshare.14615233
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22697216
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753092
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753032
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22697240
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753047
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753053
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753041
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753059
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753074
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22697219
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753056
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22697252
Ji, T., Yang, Y., Yu, J., Yin, H., Chu, X., Yang, P., Xu, L., Wang, X., Hu, S., Li, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753089
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22697249
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.